Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.

Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.

老虎证券老虎证券2026/07/06 12:51
Show original
This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

CoreWeave (CRWV.US) to raise at least $4 billion after raising revenue guidance: AI computing power provider begins credit leap from "junk" to "investment grade"

AI computing power provider CoreWeave (CRWV.US), after raising its annual sales forecast and alleviating investor concerns about its heavily debt-laden business model, plans to raise at least $4 billion through an investment-grade loan.

智通财经•2026/11/11 23:27
CoreWeave (CRWV.US) to raise at least $4 billion after raising revenue guidance: AI computing power provider begins credit leap from "junk" to "investment grade"